Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T in Active Systemic Lupus Erythematosus
NCT06106906Phase 2Recruiting
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) in systemic lupus erythematosus (SLE). Started Jun 2024; status: recruiting.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06106906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06106906.